Results 71 to 80 of about 76,053 (241)

Treatment of a mixed acinar-endocrine carcinoma with uptake on 68Gallium-DOTATOC positron emission tomography-computed tomography : a case report [PDF]

, 2017
The case of a 35-year old female patient with a diagnosis of metastatic mixed acinar-endocrine carcinoma (MAEC) is investigated in the present study.
De Both, Anneleen, De Man, Marc, Geboes, Karen, Hoorens, Anne, Troisi, Roberto, Van Vlierberghe, Hans   +5 more
core   +2 more sources

Main factors associated with variability in the assessment of the objective response rate. A re‐analysis of the PHEREXA phase 3 clinical trial

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Local investigators (LIs) overestimate the objective response rate (ORR) in comparison to Blinded Independent Central Reviewers (BICR) in oncology. In this study, we re‐analysed data obtained in the PHEREXA trial (NCT01026142) with the following aims: i) to confirm at the single‐patient level the discrepancy observed by analysing ...
Gennaro Daniele, Tommaso Giovagnoli, Pierluigi Navarra, Cinzia Dello Russo   +3 more
wiley   +1 more source

Targeted therapies in the management of locally advanced and metastatic pancreatic cancer: a systematic review [PDF]

, 2018
Pancreatic cancer has a dismal prognosis particularly in patients presenting with unresectable tumors. We performed a bibliometric analysis of clinical trials for pancreatic cancer conducted between 2014-2016 focusing on patients that presented with ...
Biankin, Andrew V., Khachigian, Levon M., Parish, Christopher R., Sheahan, Anjali V.   +3 more
core   +1 more source

Consistency and clarity of pharmacogenomic guidance in UK medicine patient information leaflets: A cross‐sectional analysis

British Journal of Clinical Pharmacology, EarlyView.
Pharmacogenomic (PGx) information has the potential to support the safe and effective use of medicines, yet there is uncertainty about how this information can be best communicated to patients. Summaries of product characteristics (SmPCs) and patient information leaflets (PILs) for all UK‐approved medicines with strong evidence supporting a PGx ...
Parth Narlawar, Chloe Ratcliffe, Videha Sharma, William G. Newman, Munir Pirmohamed, John McDermott   +5 more
wiley   +1 more source

Management of severe capecitabine-induced corneal toxicity

American Journal of Ophthalmology Case Reports
Purpose: To describe the clinical presentation and management of severe capecitabine-induced corneal toxicity. Observations: A 71-year-old woman presented with severe bilateral vision loss. Four months earlier, capecitabine was initiated for a metastatic
Mathieu Heyvaert, Hannelore Denys, Jo Van Dorpe, Dimitri Roels   +3 more
doaj   +1 more source

Neutrophil-to-lymphocyte ratio as a prognostic factor for patients with metastatic or recurrent breast cancer treated using capecitabine: a retrospective study

BMC Cancer, 2022
Background Eribulin or capecitabine monotherapy is the next cytotoxic chemotherapy option for patients with metastatic or recurrent breast cancer who have previously received an anthracycline or a taxane. However, it is unclear what factors can guide the
Shigemasa Takamizawa, Tatsunori Shimoi, Natsuko Satomi-Tsushita, Shu Yazaki, Toshihiro Okuya, Yuki Kojima, Hitomi Sumiyoshi-Okuma, Tadaaki Nishikawa, Maki Tanioka, Kazuki Sudo, Emi Noguchi, Kan Yonemori   +11 more
doaj   +1 more source

Cost‐effectiveness of DPYD genotyping prior to fluoropyrimidine‐based treatment for colorectal cancer in Wales

British Journal of Clinical Pharmacology, EarlyView.
Abstract Background Regulatory guidance in the United Kingdom advises DPYD genotyping prior to fluoropyrimidine‐based treatment. This economic evaluation estimated the costs and outcomes associated with DPYD screening prior to prescribing fluoropyrimidines for colorectal cancer in Wales and also considers additional variants to those included in ...
Catrin O. Plumpton, Sian M. Morgan, Richard A. Adams, Samantha Cox, Angharad A. Rudkin, Megan Fealey, Craig Barrington, Michelle D. Wood, Dyfrig A. Hughes   +8 more
wiley   +1 more source

Rapid Breast Cancer Disease Progression Following Cyclin Dependent Kinase 4 and 6 Inhibitor Discontinuation. [PDF]

, 2017
Background: CDK 4 and 6 inhibitors (CDK4/6i), which arrest unregulated cancer cell proliferation, show clinical efficacy in breast cancer. Unexpectedly, a patient treated on a CDK4/6i-based trial, as first-line therapy in metastatic breast cancer ...
Abouharb, Sausan, Bashour, Sami I, Brown, Powel H, Doostan, Iman, Ibrahim, Nuhad K, Karuturi, Meghan, Keyomarsi, Khandan, Koenig, Kimberly B, Litton, Jennifer K, Moulder-Thompson, Stacy L, Tripathy, Debasish, Ueno, Naoto T, Valero, Vicente   +12 more
core   +2 more sources

Tackling cancer stemness with nanotechnology in the era of precision medicine

BMEMat, EarlyView.
Precise customization of nanoparticles (NPs) enables active targeting of cancer stem cells (CSCs), thereby improving drug delivery and therapeutic efficacy. NP‐based probing enhances CSC detection through imaging and liquid biopsy, whereas diverse therapeutic payloads improve therapeutic outcomes.
Shaolei Guo, Shun Yao, Lihui Meng, Chunyuan Chen, Yuechu Lucinda Lu, Rong Lu, Kashif Rafiq Zahid, Umar Raza, Qingzhi Wu, Wenli Chen   +9 more
wiley   +1 more source

Use of omeprazole, the proton pump inhibitor, as a potential therapy for the capecitabine-induced hand-foot syndrome

Scientific Reports, 2021
Hand-foot syndrome (HFS), also known as palmar-plantar erythrodysesthesia (PPE), is a major side effect of capecitabine. Although the pathogenesis of HFS remains unknown, some studies suggested a potential involvement of inflammation in its pathogenesis.
Shiori Hiromoto, Takehiro Kawashiri, Natsumi Yamanaka, Daisuke Kobayashi, Keisuke Mine, Mizuki Inoue, Mayako Uchida, Takao Shimazoe   +7 more
doaj   +1 more source